Combined therapy drug comprising Anti-her2 bispecific antibody and use thereof

Through the combined use of anti-HER2 bispecific antibodies and docetaxel albumin composition, the problems of poor efficacy and low drug delivery in the treatment of HER2-positive breast cancer were solved, and more efficient and safer treatment effects were achieved , providing a new option for first-line treatment for patients with HER2-positive recurrent metastatic breast cancer.

WO2024230772A1PCT designated stage expired Publication Date: 2024-11-14JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/091943
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing treatment methods for HER2-positive breast cancer have poor efficacy, low drug delivery convenience and safety problems. Especially patients with recurrent metastatic breast cancer need urgently for more effective, safe and convenient treatment plans.

Method used

Using anti-HER2 bispecific antibodies and docetaxel albumin compositions, a new drug combination is formed for the treatment of HER2 Positive recurrent metastatic breast cancer improves efficacy and simplifies the administration process.

Benefits of technology

This composition significantly improves the anti-tumor efficacy of HER2-positive breast cancer, has good overall safety and is convenient to administer, provides a better treatment option, and significantly improves the quality of life and survival of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024091943-FTAPPB-I100001
    Figure PCTCN2024091943-FTAPPB-I100001
  • Figure PCTCN2024091943-FTAPPB-I100002
    Figure PCTCN2024091943-FTAPPB-I100002
  • Figure PCTCN2024091943-FTAPPB-I100003
    Figure PCTCN2024091943-FTAPPB-I100003
Patent Text Reader

Abstract

A combined therapeutic drug comprising an anti-HER2 bispecific antibody and a use thereof, especially a use of an anti-HER2 bispecific antibody combined with a docetaxel albumin composition in the preparation of a medicament for treating advanced malignant solid tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Combination therapy containing anti-HER2 bispecific antibodies and uses thereof Technical Field

[0001] The present invention relates to the field of biopharmaceuticals, and more specifically, to a combination therapeutic drug comprising an anti-HER2 bispecific antibody and uses thereof, in particular, to the use of an anti-HER2 bispecific antibody combined with docetaxel and albumin in the preparation of a drug for treating advanced malignant solid tumors. Background Art

[0002] The latest data released by the International Agency for Research on Cancer shows that in 2020, there were 2.26 million new cases of breast cancer worldwide, overtaking lung cancer as the world's leading new cancer. There were also 684,000 deaths, making it the leading cause of cancer death among women. In my country, 416,000 new cases of breast cancer were reported, accounting for 18.4% of the global total, and 117,000 deaths, representing 17.1% of global breast cancer deaths. This disease continues to rise annually, posing a serious threat to the lives and health of Chinese women and has become a key focus of cancer prevention and treatment in my country.

[0003] Breast cancer is divided into different histopathological subtypes based on the expression of estrogen receptors / progesterone receptors and human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancer accounts for approximately 15-20% of all breast cancers. Compared with Western countries, the proportion of HER2-positive breast cancer in China is even higher, at 20-30%. HER2-positive is a more aggressive breast cancer subtype that affects younger patients. Compared with hormone receptor-positive / HER2-negative and triple-negative breast cancer, HER2-positive breast cancer is more likely to present at stage III-IV at initial diagnosis, with a higher histological grade, and most patients are under 65 years of age at initial diagnosis. Currently, approved drugs for the treatment of HER2-positive breast cancer in my country include trastuzumab, pertuzumab, lapatinib, neratinib, pyrotinib, and trastuzumab emtansine (T-DM1). These drugs are used throughout the treatment of HER2-positive breast cancer, including neoadjuvant therapy, postoperative adjuvant therapy, and systemic treatment for recurrence and metastasis. Despite this, the main purpose of treatment for recurrent and metastatic breast cancer is still palliative salvage therapy, which needs further improvement.

[0004] In China, approximately 20% of patients present with advanced breast cancer (stage III / IV) at initial diagnosis. Furthermore, approximately 10% of patients with HER2-positive early-stage disease will experience disease recurrence three years after radical surgery. Although first-line trastuzumab combined with pertuzumab and docetaxel significantly improves progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive metastatic breast cancer, the majority of patients experience disease progression despite treatment, necessitating the continued need for new, more effective treatment options. Furthermore, the trastuzumab combined with pertuzumab and docetaxel regimen requires cyclical administration until disease progression or intolerance. Each three-week cycle requires a 30-60 minute intravenous infusion of pertuzumab (60 minutes for the loading dose) and a 30-90 minute intravenous infusion of trastuzumab (90 minutes for the loading dose), with a 30-60 minute observation period recommended between doses. This prolonged, repeated intravenous infusion is inconvenient, requiring prolonged hospital stays and increasing the risk of nosocomial infection. Furthermore, it creates significant resource utilization challenges that require further resolution. In summary, HER2-positive breast cancer urgently needs a more effective, safe and convenient first-line treatment option.

[0005] Docetaxel is a semi-synthetic product of a non-cytotoxic precursor (10-deacetylbaccatin III) extracted from the needles of Taxus chinensis. It is a paclitaxel analogue with stronger anti-tumor activity than paclitaxel. Docetaxel is poorly water-soluble. The current commercial formulation is a regular injection, originally developed by Sanofi under the trade name TAXOTERE. The usual dosage is 75 mg / m2 once every 3 weeks as a 1-hour intravenous infusion. 2 However, Docetaxel injection, represented by acetaminophen, may cause severe allergic reactions due to the use of ethanol and Tween 80 in its formula, requiring dexamethasone pretreatment and poor patient compliance; in addition, ethanol can affect the central nervous system, requiring a lower infusion rate to alleviate poisoning symptoms.

[0006] Summary of the Invention

[0007] In response to the deficiencies of the prior art, the present invention provides a combination drug for treating cancer, which combines an anti-HER2 bispecific antibody with a docetaxel albumin composition for the treatment of HER2-positive recurrent metastatic breast cancer. It has superior anti-tumor efficacy compared to existing standard treatment regimens, and has good overall safety and more convenient administration. It can provide such patients with a first-line treatment option with better efficacy, good safety, and more convenient treatment.

[0008] In a first aspect, the present invention provides a use of an anti-HER2 antibody and a second therapeutic agent in the preparation of a medicament for treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

[0009] In a second aspect, the present invention provides a use of an anti-HER2 antibody in the preparation of a medicament for enhancing the efficacy of a second therapeutic agent in treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

[0010] In a third aspect, the present invention provides a method for treating cancer using an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin combination.

[0011] In a fourth aspect, the present invention provides a pharmaceutical composition, a kit, or a medicine box for treating cancer, comprising an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

[0012] All of the above:

[0013] In some embodiments, the combination of the anti-HER2 antibody and the second therapeutic agent is synergistic in treating cancer.

[0014] In some embodiments, the anti-HER2 antibody is an anti-HER2 bispecific antibody.

[0015] In some embodiments, the anti-HER2 antibody is a bispecific antibody targeting different epitopes of the human HER2 protein.

[0016] In some embodiments, the anti-HER2 antibody is a bispecific antibody targeting different epitopes of the human HER2 protein, wherein the different epitopes of the HER2 protein are domain II and domain IV thereof.

[0017] In some embodiments, the anti-HER2 antibody is a recombinant humanized antibody. In some embodiments, the anti-HER2 antibody comprises two common light chains with identical sequences. In some embodiments, the common light chain comprises a CDR-L1 as set forth in SEQ ID NO: 1, a CDR-L2 as set forth in SEQ ID NO: 2, and a CDR-L3 as set forth in SEQ ID NO: 3. In some embodiments, the common light chain comprises a light chain variable region as set forth in SEQ ID NO: 4, or its light chain variable region consists of the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the common light chain comprises or consists of the amino acid sequence set forth in SEQ ID NO: 5.

[0018] In some embodiments, the common light chain of the anti-HER2 antibodies is of the kappa subtype.

[0019] In some embodiments, the anti-HER2 antibody comprises two heavy chains with different sequences. In some embodiments, the heavy chain comprises a heavy chain I that targets domain II of the HER2 protein. In some embodiments, the heavy chain I comprises CDR-H1-1 as set forth in SEQ ID NO:6, CDR-H1-2 as set forth in SEQ ID NO:7, and CDR-H1-3 as set forth in SEQ ID NO:8. In some embodiments, the heavy chain I comprises a heavy chain I variable region as set forth in SEQ ID NO:9 or consists of the amino acid sequence set forth in SEQ ID NO:9. In some embodiments, the heavy chain I comprises or consists of the amino acid sequence set forth in SEQ ID NO:10 or SEQ ID NO:16.

[0020] In some embodiments, the anti-HER2 antibody comprises two heavy chains with different sequences. In some embodiments, the heavy chain comprises a heavy chain II that targets domain IV of the HER2 protein. In some embodiments, the heavy chain II comprises CDR-H2-1 as set forth in SEQ ID NO: 11, CDR-H2-2 as set forth in SEQ ID NO: 12, and CDR-H2-3 as set forth in SEQ ID NO: 13. In some embodiments, the heavy chain II comprises a heavy chain II variable region as set forth in SEQ ID NO: 14 or consists of the amino acid sequence set forth in SEQ ID NO: 14. In some embodiments, the heavy chain II comprises or consists of the amino acid sequence set forth in SEQ ID NO: 15 or SEQ ID NO: 17.

[0021] In some embodiments, the heavy chain comprises heavy chain I targeting domain II of the HER2 protein and heavy chain II targeting domain IV of the HER2 protein, wherein heavy chain I and heavy chain II are as described above.

[0022] In some embodiments, the anti-HER2 antibody is KN026 (hereinafter referred to as KN026) produced by Jiangsu Alphamab Biopharmaceutical Co., Ltd.

[0023] In some embodiments, the cancer includes but is not limited to a hematological tumor or a solid tumor.

[0024] In some embodiments, the cancer is a hematologic malignancy. In some embodiments, the cancer is a lymphoma or leukemia. In some embodiments, the lymphoma or leukemia includes, but is not limited to, myeloma, B-cell lymphoma, mantle cell lymphoma, non-Hodgkin's B-cell lymphoma, non-Hodgkin's T-cell lymphoma, cutaneous lymphoma, anaplastic large cell lymphoma, multiple myeloma, indolent non-Hodgkin's lymphoma, plasmacytoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma. In some embodiments, the above cancer is relapsed or refractory.

[0025] In some embodiments, the cancer is a solid tumor. In some embodiments, the solid tumor includes but is not limited to bladder cancer, brain cancer, breast cancer, cervical cancer, breast cancer, endometrial cancer, esophageal squamous cell carcinoma, gastric cancer, head tumor, pancreatic cancer, bile duct cancer, colorectal cancer, eye cancer, head and neck squamous cell carcinoma, urothelial carcinoma, kidney cancer, liver cancer, lymph node cancer, lung cancer, oral cancer, neck tumor, ovarian cancer, prostate cancer, testicular cancer, laryngeal cancer and uterine cancer, melanoma, skin cancer, salivary gland cancer, soft tissue sarcoma and osteosarcoma. In some embodiments, the above cancer is relapsed or refractory.

[0026] In some embodiments, the cancer is selected from breast cancer.

[0027] In some embodiments, the breast cancer is HER2-positive breast cancer, preferably IHC3+ HER2-positive breast cancer or IHC2+ and ISH-positive HER2-positive breast cancer. In some embodiments, the breast cancer is selected from hormone receptor-positive or -negative HER2-positive breast cancer, preferably HER2-positive breast cancer with both estrogen receptor and progesterone receptor negative, or HER2-positive breast cancer with estrogen receptor and / or progesterone receptor positive.

[0028] In some embodiments, the breast cancer includes: ductal carcinoma, lobular carcinoma, medullary carcinoma, glial carcinoma, tubular carcinoma, inflammatory breast cancer, triple negative breast cancer (TNBC).

[0029] In some embodiments, the breast cancer is recurrent or metastatic breast cancer. In some embodiments, the breast cancer is selected from breast cancer with visceral metastasis or breast cancer without visceral metastasis.

[0030] In some embodiments, the breast cancer is recurrent and metastatic breast cancer.

[0031] In some embodiments, the breast cancer is recurrent or metastatic breast cancer that has not previously received systemic chemotherapy and / or HER2-targeted therapy for recurrent or metastatic breast cancer, or breast cancer that recurred more than 12 months after the end of neoadjuvant therapy or adjuvant therapy or HER2-targeted therapy. The systemic chemotherapy is selected from taxane chemotherapy drugs such as docetaxel, albumin-paclitaxel, capecitabine, vinorelbine, etc.; the HER2 targeted therapy is selected from trastuzumab, pertuzumab, pyrotinib, trastuzumab-emtansine conjugate (tdm-1); the neoadjuvant treatment regimen is selected from: trastuzumab, taxanes and pertuzumab with or without carboplatin; anthracyclines combined with cyclophosphamide and taxanes, trastuzumab, pertuzumab; the adjuvant treatment regimen is selected from: anthracyclines combined with cyclophosphamide sequentially with taxanes combined with trastuzumab, pertuzumab; docetaxel combined with carboplatin combined with trastuzumab, pertuzumab; trastuzumab / pertuzumab sequentially with neratinib; tdm-1.

[0032] In some embodiments, the anti-HER2 antibody and the second therapeutic agent are the only therapeutically active ingredients.

[0033] In some embodiments, the uses, methods, pharmaceutical compositions, or kits described herein further comprise a third therapeutic agent, which is a chemotherapeutic agent. The chemotherapeutic agent is, for example, bendamustine, chlorambucil, cyclophosphamide, doxorubicin, vincristine, fludarabine, carboplatin, cisplatin, or any combination thereof.

[0034] In some embodiments, the uses, methods, pharmaceutical compositions, or kits described herein further comprise a drug to support treatment, such as granulocyte colony stimulating factor (G-CSF).

[0035] In some embodiments, the anti-HER2 antibody and the second therapeutic agent are contained in the same dosage unit.

[0036] In some embodiments, the anti-HER2 antibody and the second therapeutic agent are each contained in separate dosage units.

[0037] In some embodiments, the medicaments, pharmaceutical compositions, kits, or kits described herein are administered to a patient or subject in need thereof in a clinically acceptable manner, preferably by intravenous infusion. Accordingly, the anti-HER2 antibody and the second therapeutic agent are in a clinically acceptable formulation, preferably in an injectable dosage form, including a liquid injection, a powder for injection, or a tablet for injection.

[0038] In some embodiments, the anti-HER2 antibody is formulated into a preparation, and the content of the anti-HER2 antibody or a pharmaceutically acceptable form thereof (calculated as anhydrous anti-HER2 antibody) in each preparation unit is in the range of about 0.01 mg to about 400 mg, preferably about 300-400 mg, more preferably about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg.

[0039] In some embodiments, the anti-HER2 antibody is administered at a dose of about 0.01 mg / kg-100 mg / kg, preferably about 20-40 mg / kg, about 20 mg / kg-30 mg / kg, about 25 mg / kg-35 mg / kg, and more preferably about 30 mg / kg.

[0040] In some embodiments, the anti-HER2 antibody is administered in one or more dosing cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 or more dosing cycles). Preferably, it is administered in three or more dosing cycles. In some embodiments of the present invention, the dosing cycle of the anti-HER2 antibody continues until the clinical benefit is lost (e.g., confirmed as disease progression, drug resistance, death or unacceptable toxicity).

[0041] In some embodiments, the docetaxel albumin composition is formulated into a preparation, wherein each preparation unit contains 50-100 mg, preferably 70-90 mg, and more preferably about 80 mg, of docetaxel (calculated as anhydrous docetaxel).

[0042] In some embodiments, preferably, the docetaxel albumin composition is a powder for injection, which contains about 50-100 mg of active ingredient per vial, preferably about 70-90 mg per vial, and more preferably about 80 mg per vial, calculated as anhydrous docetaxel.

[0043] In some embodiments, the docetaxel albumin composition is administered at a dose of about 60-125 mg / m 2 , preferably about 60-100 mg / m 2 , more preferably about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 .

[0044] In some embodiments, the docetaxel albumin composition is administered for one or more dosing cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 or more dosing cycles). Preferably, the composition is administered for three or more dosing cycles. In some embodiments of the invention, the docetaxel albumin composition is administered for a period of time until loss of clinical benefit (e.g., confirmed as disease progression, drug resistance, death, or unacceptable toxicity).

[0045] In some embodiments of the invention, the length of each of the one or more dosing cycles is 14 days. In some embodiments of the invention, the length of each of the one or more dosing cycles is 21 days. In some embodiments of the invention, the length of each of the one or more dosing cycles is 28 days. Preferably, the length of each of the one or more dosing cycles is 21 days.

[0046] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin combination is administered at a frequency of QW (once a week), Q2W (once every two weeks), Q3W (once every three weeks) or Q4W (once every four weeks).

[0047] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once every 3 weeks (Q3W), with 21 days as one treatment cycle.

[0048] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once every four weeks (Q4W), with 28 days as one treatment cycle.

[0049] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once every 2 weeks (Q2W), with a treatment cycle of 14 days or 28 days.

[0050] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once a week (QW) for 3 consecutive weeks, followed by a one-week rest period, with 28 days as one treatment cycle.

[0051] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once a week (QW) for 2 consecutive weeks followed by a one-week rest period, with 21 days as one treatment cycle.

[0052] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered on about day 1 (eg, day 1, 2, 3, or 4) of each dosing cycle.

[0053] In some embodiments of the present invention, the anti-HER2 antibody is administered before or after the docetaxel albumin composition.

[0054] The drug, pharmaceutical composition, kit or drug box described in the present application is administered to a patient or subject in need thereof in a therapeutically effective amount for the treatment of breast cancer. The breast cancer is as described above.

[0055] In some embodiments, the medicament, pharmaceutical composition, kit or drug box of the present application comprises an anti-HER2 antibody and a docetaxel albumin composition, which is administered to a patient or subject in need thereof in a therapeutically effective amount for the treatment of breast cancer, wherein the breast cancer is as described above.

[0056] In some embodiments, the anti-HER2 antibody is administered once every 2-4 weeks, preferably once every 3 weeks; administered on day 1 of each cycle, the dose is about 20-40 mg / kg, preferably about 25-35 mg / kg, more preferably about 30 mg / kg; the first intravenous drip is 90 min ± 15 min, and the subsequent cycles are intravenous drips of 60 min ± 15 min. In some embodiments, the docetaxel albumin composition is administered once every 2-4 weeks, preferably once every 3 weeks; administered on day 1 of each cycle, the dose is about 60-125 mg / m 2 , preferably about 60-100 mg / m 2 , for example, about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 , intravenous drip for 60min±10min.

[0057] In some embodiments, the anti-HER2 antibody is administered once every 3 weeks, on the first day of each cycle, at a dose of about 30 mg / kg, with an intravenous drip of 90 min ± 15 min for the first cycle and 60 min ± 15 min for subsequent cycles. In some embodiments, the docetaxel albumin composition is administered once every 3 weeks, on the first day of each cycle, at a dose of about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 , intravenous drip for 60min±10min.

[0058] In some embodiments, the docetaxel albumin composition described herein is prepared using the method disclosed in WO2022184164A1. Studies have shown that both the pre-lyophilized suspension and the reconstituted suspension after lyophilization are stable at room temperature for at least 24 hours and refrigerated for at least 10 days, without turbidity or nanoparticle sedimentation. Compared to commercially available albumin-bound drugs, which are only stable for 8 hours after reconstitution, this product significantly reduces clinical limitations.

[0059] The docetaxel albumin composition described herein is a docetaxel albumin nanoparticle composition comprising docetaxel and acid-denatured albumin, and optionally comprising an osmotic pressure regulator and / or a pH regulator. The acid-denatured albumin is obtained by denaturing human serum albumin by adding acid to the albumin and adjusting it to an appropriate pH value. Preferably:

[0060] (1) The acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids. The acidic amino acids or acidic polypeptides include but are not limited to cysteine ​​hydrochloride, glutathione, etc.; the organic acids include but are not limited to citric acid, tartaric acid, etc.; the inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, etc. The acid is preferably cysteine ​​hydrochloride, glutathione, hydrochloric acid, and more preferably cysteine ​​hydrochloride; and / or

[0061] (2) the appropriate pH value is preferably about 3.5 to 5.5, preferably about 3.5 to 5.0, more preferably about 3.8 to 4.7, more preferably about 4.0 to 4.5; and / or

[0062] (3) based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), more preferably 1:(4.0-6.0); most preferably, about 1:4.5; and / or

[0063] (4) The content of sodium octanoate in the human serum albumin is not higher than 0.08 mmol / g protein, preferably 0.03-0.08 mmol / g protein, further preferably 0.04-0.08 mmol / g protein, and more preferably 0.04-0.07 mmol / g protein.

[0064] In some embodiments, the particle size of the docetaxel albumin nanoparticles is about 60-200 nm, preferably about 90-150 nm, and more preferably about 90-135 nm.

[0065] The type of the osmotic pressure regulator is not particularly limited, and can be selected from sodium chloride, glucose, phosphate or citrate, etc., preferably sodium chloride. In some embodiments, the osmotic pressure regulator is sodium chloride, and the weight ratio of sodium chloride to docetaxel is (0.75-9):1, preferably (1-7):1, preferably (1.5-4.5):1, and most preferably about 2.25:1.

[0066] The pH adjuster is not particularly limited in type and is used to adjust the pH value within an appropriate range. Preferably, the pH value range is 3.4-5.8; preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8, and most preferably about 4.1.

[0067] The docetaxel albumin composition described herein has no particular requirement for whether the docetaxel is in the form of a hydrate and can be selected from any of anhydrous docetaxel, docetaxel hemihydrate, or docetaxel trihydrate. Preferably, the docetaxel is selected from anhydrous docetaxel. The docetaxel content described herein is calculated based on anhydrous docetaxel.

[0068] The drug described herein comprises a docetaxel-albumin combination. The drug is in a clinically acceptable dosage form, preferably an injection, more preferably a liquid injection or a lyophilized powder injection. For example, the docetaxel (albumin-bound) for injection used in the specific embodiments is also known as DTX-HSA.

[0069] In some embodiments, the drug is a liquid injection having a pH of 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of the docetaxel albumin nanoparticles in the liquid injection is about 60-200 nm, preferably about 90-150 nm, more preferably about 90-135 nm; the liquid injection contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v), more preferably 0.9% (w / v). In some embodiments, the liquid injection contains 2-10 mg / ml of docetaxel, preferably 2-8 mg / ml.

[0070] In some embodiments, the drug is a lyophilized powder injection containing sodium chloride, with a weight ratio of sodium chloride to docetaxel of (0.75-9):1, preferably (1-7):1; preferably (1.5-4.5):1, and most preferably about 2.25:1. The particle size of the docetaxel albumin nanoparticles is about 60-200 nm, preferably about 90-150 nm, and more preferably about 90-135 nm. The pH of the suspension used to prepare the lyophilized powder injection before lyophilization is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8, and most preferably about 4.1.

[0071] The lyophilized powder injection is reconstituted into a suspension using a reconstitution medium before use. The reconstitution medium is selected from water for injection, sodium chloride solution or glucose solution, preferably water for injection. The pH value of the reconstituted suspension obtained is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the reconstituted suspension is about 60-200 nm, preferably about 90-150 nm, more preferably about 90-135 nm. The reconstituted suspension contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v), more preferably 0.9%. In some embodiments, the reconstituted suspension contains 2-10 mg / ml of docetaxel, preferably 2-8 mg / ml.

[0072] The preparation method of the docetaxel albumin composition described in the present application comprises the following steps:

[0073] (1) dissolving docetaxel in an organic solvent to obtain an organic phase solution;

[0074] (2) taking a human albumin solution, adding acid to adjust the pH value to obtain an acid-denatured albumin aqueous solution; and taking another salt solution;

[0075] (3) mixing the organic phase solution, the aqueous phase solution, and the salt solution to carry the drug to obtain a drug-loaded solution;

[0076] (4) Dialysis to obtain a dialyzed suspension.

[0077] Wherein, step (2) optionally comprises the step of diluting the human serum albumin solution with water for injection to obtain an albumin dilution solution before adding acid to adjust the pH value.

[0078] Wherein, step (2) optionally comprises an incubation step after adding acid to adjust the pH value.

[0079] Wherein, step (3) optionally includes a cooling step after mixing the drug-loaded mixture.

[0080] Wherein, step (4) optionally comprises, before dialysis, concentrating the drug-loaded solution obtained in step (3) to obtain a concentrated solution.

[0081] Wherein, after dialysis, step (4) optionally comprises a concentration or dilution step to adjust the concentration of docetaxel in the suspension after dialysis.

[0082] Wherein, step (4) optionally includes step (5) sterilization filtration.

[0083] Wherein, step (5) optionally comprises step (6) freeze-drying.

[0084] Wherein, the docetaxel in step (1) is in any form, preferably anhydrous docetaxel, docetaxel hemihydrate, or docetaxel trihydrate. The mass ratio of docetaxel to human albumin, calculated as anhydrous docetaxel, is 1:(2.0-10.0), preferably 1:(3.0-7.0), more preferably 1:(4.0-6.0), and most preferably about 1:4.5).

[0085] The organic solvent in step (1) is selected from water-miscible solvents, such as ethanol, methanol, acetone, DMSO, etc., preferably ethanol. The organic phase solution contains 45-90 mg / ml of docetaxel, preferably 45-70 mg / ml, based on anhydrous docetaxel.

[0086] Wherein, the content of sodium octanoate in the human albumin solution in step (2) is not higher than 0.12 mmol / g protein, preferably not higher than 0.08 mmol / g protein, preferably 0.045-0.08 mmol / g protein.

[0087] Wherein, in step (2), the albumin diluent contains 6-25 mg / ml of albumin, preferably 10-20 mg / ml, more preferably 12-18 mg / ml, and even more preferably about 15 mg / ml.

[0088] Wherein, in step (2), the acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids. The acidic amino acids or acidic polypeptides include but are not limited to cysteine ​​hydrochloride, glutathione, etc.; the organic acids include but are not limited to citric acid, tartaric acid, etc.; the inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, etc. The acid is preferably cysteine ​​hydrochloride, glutathione, hydrochloric acid, and more preferably cysteine ​​hydrochloride. The pH value is preferably 3.5-5.5, preferably 3.5-5.0, more preferably 3.8-4.7, more preferably 4.0-4.5, and most preferably about 4.1.

[0089] Wherein, in step (2), the incubation refers to adding acid to adjust the pH value, heating to 35°C-42°C, preferably 38°C-42°C; incubating for more than 30 minutes, preferably 30 minutes-60 minutes.

[0090] The salt solution in step (2) is selected from an aqueous solution of sodium chloride, potassium chloride, sodium sulfate or magnesium sulfate, preferably an aqueous solution of sodium chloride; the concentration of the salt solution is not less than 2%, preferably 2% to 35%, more preferably 10% to 20%.

[0091] Wherein, in step (3), the drug loading condition is to heat the organic phase solution and the aqueous phase solution to 35°C-42°C, preferably 38°C-42°C, and mix the three to load the drug.

[0092] The cooling in step (3) refers to cooling to below room temperature, preferably 0-20°C, more preferably 7-15°C.

[0093] Wherein, the concentrated solution in step (4) contains about 4-10 mg / ml of docetaxel, preferably 6-10 mg / ml, more preferably 7-9 mg / ml, and more preferably 8 mg / ml.

[0094] Wherein, step (4) dialyzes to remove excess small molecule compounds. There is no particular limitation on the type and dosage of the dialysate and the molecular weight cutoff of the dialysis membrane. Those skilled in the art can make a choice based on common technical knowledge or experience. For the convenience of further preparation and clinical use, the dialysate is preferably an aqueous solution of a clinically acceptable osmotic pressure regulator, such as an aqueous solution of sodium chloride, glucose, phosphate or citrate. In some embodiments, sodium chloride solution is used as the dialysate for dialysis in step (4). The molecular weight cutoff of the dialysis membrane is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa. The volume of the dialysate is not less than 3 times that of the drug-loaded solution or concentrate, preferably 3-10 times, more preferably 3-6 times. The concentration of the sodium chloride solution is not higher than 1.8% (w / v), preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v).

[0095] In some embodiments, the human albumin solution used in step (2) needs to have its sodium octanoate content adjusted in advance. Those skilled in the art can select an appropriate method to adjust the sodium octanoate content in the human albumin solution based on common technical knowledge or experience, including but not limited to dialysis.

[0096] In some embodiments, the method for adjusting the content of sodium octanoate in a human serum albumin solution is: taking a commercially available human serum albumin solution, diluting it with water for injection or normal saline to obtain a diluted albumin solution; dialyzing the diluted albumin solution with water for injection or normal saline as a dialysate to partially remove the sodium octanoate, thereby obtaining a human serum albumin solution with a low sodium octanoate content.

[0097] In some embodiments, the dilution factor of the human albumin solution is not less than 4 times, preferably 4-7 times. For the dialysis, the molecular weight cut-off of the dialysis membrane is 10-50 KDa, preferably 10-30 KDa, more preferably 10 KDa or 30 KDa. The volume of the dialysate can be determined by a person skilled in the art through routine testing based on the required sodium octanoate content. Preferably, the volume of the dialysate is about 3 times or more of the volume of the diluted albumin solution, preferably 3-10 times, more preferably 3-6 times.

[0098] The human albumin solution with a low sodium octanoate content contains less than 0.16 mmol / g of sodium octanoate per gram of protein, preferably less than 0.12 mmol / g of protein, preferably less than 0.10 mmol / g of protein, and preferably less than 0.08 mmol / g of protein. The human albumin solution with a low sodium octanoate content can be used directly to prepare the docetaxel albumin nanoparticle composition described herein, or can be mixed with human albumin solutions with other sodium octanoate contents in proportion to obtain the desired sodium octanoate content, and then used to prepare the docetaxel albumin nanoparticle composition.

[0099] In the preparation method, the dialysis step will remove excess small molecule compounds in the drug-loaded solution or the concentrated solution. For example, in some embodiments, step (2) uses acidic amino acids or acidic polypeptides to adjust the pH to prepare acid-denatured albumin; the dialysis step substantially removes excess acidic amino acids or acidic polypeptides; and the composition contains almost no free acidic amino acids or acidic polypeptides. The "almost no free acidic amino acids or acidic polypeptides" means that the content of free acidic amino acids or acidic polypeptides in the composition is less than 0.25% (w / w) of docetaxel. For example, in some embodiments, cysteine ​​hydrochloride or glutathione is used to adjust the pH to prepare acid-denatured albumin, and the content of free cysteine ​​or glutathione in the composition is less than 0.25% (w / w) of docetaxel.

[0100] The relevant sequences of the present invention are as follows:

[0101] It should be understood that within the scope of this application, the above-mentioned technical features of this application and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. Description of the drawings:

[0102] Figure 1: Schematic diagram of the structure of KN026. Specific implementation method:

[0103] The following examples are provided to better illustrate the present invention, but are not intended to limit the present invention to these examples. Non-essential improvements and adjustments to the embodiments made by those skilled in the art based on the above invention are still within the scope of protection of the present invention.

[0104] Unless otherwise indicated, as used herein, the singular forms "a", "an" and "the" include the plural forms as well. For example, the term "a cell" includes a plurality of cells and mixtures thereof.

[0105] As used herein, the term "about" or "approximately" refers to the usual error range of each value that is readily known to those skilled in the art. The use of "about" or "approximately" values ​​or parameters herein includes (and describes) embodiments (or examples) related to the value or parameter itself.

[0106] As used herein, the terms "comprising" or "including" are intended to include the stated elements, integers, or steps, but do not exclude any other elements, integers, or steps. In the present invention, when the terms "comprising" or "including" are used, unless otherwise indicated, the context of consisting of the stated elements, integers, or steps is also encompassed. For example, when referring to an antibody variable region "comprising" a specific sequence, it is also intended to encompass an antibody variable region consisting of the specific sequence.

[0107] As used herein, the term "cancer" refers to a proliferative disorder caused by or characterized by the proliferation of cells that have lost their susceptibility to normal growth control. The term "cancer" includes tumors and any other proliferative disorder. Cancers of the same tissue type originate from the same tissue and can be divided into different subtypes based on their biological characteristics.

[0108] As used herein, the term "treatment" refers to a clinical intervention intended to change the natural course of the individual or cell being treated during the clinical pathological process. The desired effects of treatment include delaying or reducing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis. For example, if one or more symptoms associated with cancer are alleviated or eliminated, including but not limited to reducing the proliferation of cancer cells (or eliminating cancer cells), reducing the symptoms caused by the disease, improving the quality of life of patients with the disease, reducing the dosage of other drugs required to treat the disease, delaying the progression of the disease and / or prolonging the patient's survival, then the patient has been successfully "treated."

[0109] As used herein, the term "antibody" includes monoclonal antibodies (including full-length antibodies having an immunoglobulin Fc region), antibodies with multiple epitope specificities, multispecific antibodies (such as bispecific antibodies), dimers and single-chain antibodies, as well as antibody fragments (including antigen-binding fragments such as Fab, F(ab')2 and Fv).

[0110] As used herein, the term "CDR (complementarity determining region)" refers to the amino acid sequence that together defines the binding affinity and specificity of the Fv region of an antibody. Because the specificity of an antibody lies in the structural complementarity between the antibody binding site and the antigenic determinant. The antibody binding site is composed mainly of residues from the so-called hypervariable region or complementary determining region (CDR). The light chain (L) and heavy chain (H) of an antibody each have three CDRs, and the antigen binding site of a conventional antibody includes six CDRs, which include a CDR group from each of the heavy chain variable region and the light chain variable region.

[0111] As used herein, the term "heavy chain variable region (VH)" refers to the amino-terminal variable region domain of an immunoglobulin heavy chain.

[0112] As used herein, the term "light chain variable region (VL)" refers to the amino-terminal variable region domain of an immunoglobulin light chain.

[0113] As used herein, the term "preparation unit" refers to the smallest sub-package of each pharmaceutical preparation containing an appropriate amount of active compound, such as a unit preparation in a capsule refers to a capsule, a unit preparation in a tablet refers to a tablet, a unit preparation in an injection refers to an injection, and so on for other types of preparations.

[0114] As used herein, the term "objective response rate (ORR)" is defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) during the study period using RECIST 1.1 criteria.

[0115] As used herein, the term "partial response" or "PR" refers to a decrease in the sum of the diameters of target lesions (SOD) by at least 30% compared to baseline, with no progression of non-target lesions and no new lesions, according to RECIST 1.1 criteria.

[0116] As used herein, the term "complete response" or "CR" refers to the disappearance of all non-lymph node target lesions and non-target lesions without the development of new lesions, using the RECIST 1.1 criteria.

[0117] As used herein, the term "therapeutically effective amount" refers to an amount that brings a therapeutic effect to a subject, for example, in a subject to which the amount is administered, the symptoms or state of the disease are alleviated, reduced, or eliminated, or the development of the symptoms or state of the disease is delayed or inhibited, compared to a subject not administered the amount.

[0118] As used herein, the term "intolerant" refers to a subject who has previously received anticancer therapy but developed symptoms of an adverse event (e.g., peripheral neuropathy, skin toxicity, hyperglycemia, gastrointestinal symptoms) during the first two cycles, which did not improve despite following dose adjustment guidelines, leading to treatment discontinuation, without evidence of disease progression.

[0119] As used herein, the term "CnDm" represents the mth day of the nth dosing cycle, for example, C1D1 represents the first dosing time, and C4D1 represents the first day of the fourth dosing cycle.

[0120] As used herein, the term "recurrence" refers to the appearance of new lesions after cancer (eg, breast cancer) has been previously treated with radical therapy, representing the recurrence of cancer (eg, breast cancer).

[0121] As used herein, the term "metastasis" refers to the spread of tumor lesions beyond the primary site, including the ipsilateral supraclavicular lymph nodes, ipsilateral internal mammary lymph nodes, ipsilateral axillary lymph nodes, ipsilateral chest wall, skin, etc., which is distant metastasis.

[0122] In some embodiments, the anti-HER2 antibody is composed of two different heavy chains (H) and two common light chains (L) with exactly the same sequence. Each of the common light chains has three CDRs, designated CDR-L1, CDR-L2, and CDR-L3. In some embodiments, the common light chain comprises CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2, and CDR-L3 as shown in SEQ ID NO: 3. The heavy chain comprises heavy chain I targeting domain II of the HER2 protein and heavy chain II targeting domain IV of the HER2 protein. The heavy chain I has three CDRs, designated CDR-H1-1, CDR-H1-2, and CDR-H1-3. In some embodiments, the heavy chain I comprises CDR-H1-1 as shown in SEQ ID NO: 6, CDR-H1-2 as shown in SEQ ID NO: 7, and CDR-H1-3 as shown in SEQ ID NO: 8. The heavy chain II has three CDRs, designated CDR-H2-1, CDR-H2-2, and CDR-H2-3. In some embodiments, the heavy chain II comprises CDR-H2-1 as set forth in SEQ ID NO: 11, CDR-H2-2 as set forth in SEQ ID NO: 12, and CDR-H2-3 as set forth in SEQ ID NO: 13.

[0123] In this application, heavy chain I and heavy chain II are only used to distinguish two heavy chains targeting different epitopes, and do not indicate the order or position.

[0124] The docetaxel albumin composition described herein is also referred to as docetaxel (albumin-bound). In some embodiments, the docetaxel albumin composition is a docetaxel albumin nanoparticle composition, prepared using conventional methods for preparing albumin nanoparticle drugs in the art. Because human albumin is endogenous to the human body and has excellent biocompatibility, it can serve as a natural carrier for hydrophobic drugs, increasing the solubility of poorly soluble drugs. Furthermore, albumin's unique "gp60-caveolin-SPARC" pathway can be used to enrich drugs in tumor areas, thereby enhancing therapeutic efficacy.

[0125] In some embodiments, the docetaxel albumin composition described herein is prepared with reference to the method disclosed in WO2022184164A1, the entire disclosure of which is incorporated herein by reference.

[0126] In some embodiments, the anti-Her2 bispecific antibody disclosed herein is KN026. The sequences of the two common light chains of KN026 are both the amino acid sequence set forth in SEQ ID NO:5, the sequence of heavy chain I is the amino acid sequence set forth in SEQ ID NO:10, and the sequence of heavy chain II is the amino acid sequence set forth in SEQ ID NO:15. The structure of KN026 is shown in Figure 1. The KN026 antibody can be prepared using conventional techniques in the art.

[0127] The Fab1 (heavy chain I) of the KN026 antibody protein specifically recognizes domain II of the human HER2 protein and blocks signal transduction caused by the formation of heterodimers between HER2 and other ERBB family members; the Fab2 (heavy chain II) inhibits HER2-related signaling pathways by targeting domain IV of the human HER2 protein. The two inhibitory mechanisms work synergistically, enabling the KN026 bispecific antibody to more effectively inhibit the proliferation of HER2-positive tumor cells. In addition, the CH3 domains of the two heavy chains of KN026 contain a series of asymmetric amino acid mutations to increase the yield of heterodimeric antibody proteins while retaining complete Fc function. KN026 has significant antibody-dependent cell-mediated cytotoxicity. The results of in vitro anti-tumor cell proliferation experiments showed that the above-mentioned antibody inhibited tumor cell proliferation in a dose-dependent manner. In some embodiments, the preparation of KN026 and related preparations disclosed in this application can be prepared using conventional methods in the art. For example, the preparation can be a liquid preparation. For example, the preparation can be prepared in an aqueous carrier. For example, a stabilizer may be added in an amount no greater than that which would result in a viscosity that is undesirable or unsuitable for intravenous administration. For example, the liquid formulation may further comprise one or more of a buffer, a surfactant, and a preservative.

[0128] Preparation Example

[0129] The docetaxel for injection (albumin-bound) used in the examples was produced by CSPC Pharmaceutical Group and prepared according to the method described in Example 1, Prescription 1-1 of patent WO2022184164A1. The details are as follows:

[0130] (1) Weigh 8 g of anhydrous docetaxel and dissolve it in 120 ml of ethanol to obtain an organic phase solution;

[0131] (2) Take a human albumin solution containing 36 g of albumin (the content of sodium octanoate is 0.08 mmol / g protein), dilute it with water for injection to a solution containing 15 mg / ml of albumin, then add an appropriate amount of cysteine ​​hydrochloride to adjust the pH to 4.1, and incubate at 42°C for 30 minutes to obtain an acid-denatured albumin aqueous phase solution; take 18 g of sodium chloride and prepare a 20% saline solution with water for injection;

[0132] (3) The organic phase solution and the aqueous phase solution were heated to 42°C, the organic phase, aqueous phase and salt solution were mixed to load the drug, and the resulting material was placed in an ice water bath and cooled to 15°C to obtain a drug-loaded solution;

[0133] (4) The drug-loaded solution was concentrated to a docetaxel concentration of approximately 8 mg / ml to obtain a concentrated solution; the concentrated solution was dialyzed 5 times using an isotonic sodium chloride solution (0.9%, w / v) as a dialyzate, with a dialysis membrane having a molecular weight cutoff of 30 kDa, to obtain a dialyzed suspension; then, an appropriate amount of dialyzate was added to adjust the suspension concentration to 4 mg / ml of docetaxel;

[0134] (5) Sterile filtration through a 0.45 μm + 0.2 μm membrane to obtain a suspension before lyophilization;

[0135] (6) Take the pre-lyophilized suspension obtained in step (5), freeze-dry it, and obtain a lyophilized powder.

[0136] KN026 comprises heavy chain I, heavy chain II and a common light chain, wherein the amino acid sequence of heavy chain I is shown in SEQ ID NO: 10, the amino acid sequence of heavy chain II is shown in SEQ ID NO: 15, and the amino acid sequence of the common light chain is shown in SEQ ID NO: 5.

[0137] A vector containing nucleic acid sequences encoding the aforementioned heavy chain I, heavy chain II, and common light chain was transfected into cells for expression and purification to obtain KN026. The specific preparation process can be found in patent application document WO2016110267.

[0138] Example 1: Clinical study

[0139] This is a randomized, controlled, open-label, multicenter, superiority phase III clinical study designed to compare the efficacy and safety of KN026 combined with docetaxel (albumin-bound) for injection versus trastuzumab combined with pertuzumab and docetaxel as first-line treatment for subjects with HER2-positive recurrent or metastatic breast cancer.

[0140] 1. Research Methods

[0141] 1.1 Investigational Drug Information and Dosage Regimen:

[0142] (1) Investigational drug information

[0143] All the drugs used in the trial were provided by CSPC Pharmaceutical Group (Shanghai Jinman Biotechnology Co., Ltd.). (2) Dosage regimen for the experimental group

[0144] ①KN026

[0145] The drug is administered once every three weeks, on day 1 of each cycle, at a dose of 30 mg / kg. The first intravenous infusion is administered over 90 minutes (±15 minutes). If there are no infusion reactions, the infusion time for subsequent cycles can be adjusted to 60 minutes (±15 minutes). Each vial contains 325 mg (13 mL) of KN026 antibody. The required drug volume is calculated based on body weight, and the corresponding volume of drug is withdrawn and diluted to 250 mL of normal saline for intravenous infusion.

[0146] ② Docetaxel for injection (albumin-bound)

[0147] Administer once every 3 weeks on the first day of each cycle at a dose of 100 mg / m 2 , intravenous drip for 60min (±10min).

[0148] Each vial contains 80 mg of docetaxel (albumin-bound) powder for injection, which is dispersed and dissolved in 20 mL of water for injection to form a 4 mg / mL suspension. Calculate the appropriate volume of docetaxel based on the subject's body surface area and inject it into the infusion bag. Simultaneously, dilute the solution with the same volume of saline to a 2 mg / mL concentration for intravenous infusion.

[0149] The order of administration for the experimental group was KN026 and docetaxel for injection (albumin-bound). It was recommended to observe for at least 30 minutes between the administration of the two drugs.

[0150] To prevent severe hematotoxicity, granulocyte colony-stimulating factor (G-CSF) can be used prophylactically, and docetaxel (albumin-bound) injection should be used 24 to 72 hours after the end of the infusion.

[0151] (3) Dosage regimen for the control group:

[0152] ①Pertuzumab injection

[0153] The dose is administered once every 3 weeks, starting on day 1 of each cycle at a starting dose of 840 mg, administered as an intravenous infusion over 60 minutes (±10 minutes). Thereafter, the dose is 420 mg per cycle, administered over 30 to 60 minutes (±10 minutes). Note: If a delay in dosing results in a time interval of ≥6 weeks between two consecutive infusions, pertuzumab should be reinstituted with an 840 mg loading dose, followed by continued administration at a dose of 420 mg every 3 weeks.

[0154] Each vial contains 14 mL of concentrate at a concentration of 30 mg / mL. Calculate the appropriate volume and add to 250 mL of normal saline for intravenous infusion. Note: Do not dilute Pertuzumab in 5% dextrose solution due to its chemical and physical instability in 5% dextrose solution.

[0155] ②Trastuzumab for injection

[0156] The drug is administered once every 3 weeks, starting on day 1 of each cycle at a dose of 8 mg / kg, administered as an intravenous infusion over 90 minutes (±10 minutes). Thereafter, the dose is 6 mg / kg administered as an intravenous infusion over 30 to 90 minutes (±10 minutes) per cycle. If a delay in administration results in a time interval of ≥6 weeks between two consecutive infusions, trastuzumab should be reinstituted with an 8 mg / kg loading dose, followed by continued administration at a dose of 6 mg / kg every 3 weeks.

[0157] The corresponding medication volume was calculated based on the subject's weight and added to 250 mL of normal saline for intravenous drip.

[0158] ③Docetaxel injection

[0159] Administer once every 3 weeks on the first day of each cycle at a dose of 75 mg / m 2 , each infusion should be no less than 60 minutes.

[0160] Before docetaxel injection, pretreatment should be performed according to the instructions [oral glucocorticoids, such as dexamethasone, 16 mg per day (e.g., 8 mg twice a day) for 3 days one day before docetaxel injection] or clinical routine practice.

[0161] The order of administration for the control group was pertuzumab, trastuzumab, and docetaxel, and at least 30 minutes of observation was recommended between each administration of the two drugs.

[0162] (4) Dose adjustment

[0163] Dose reductions of KN026, trastuzumab, and pertuzumab were not permitted in this study. Dose reductions were permitted for docetaxel (albumin-bound) injection or docetaxel injection when adverse events related to treatment occurred. A maximum of two dose reductions were permitted for docetaxel (albumin-bound) injection; if a third dose reduction was required, the drug must be permanently discontinued. Only one dose reduction was permitted for docetaxel injection; if a second dose reduction was required, the drug must be permanently discontinued.

[0164] 1.2 Inclusion and Exclusion Criteria

[0165] Inclusion criteria

[0166] Subjects must meet all of the following inclusion criteria to be enrolled in this study:

[0167] 1) Voluntarily participate in this study and sign the informed consent form (ICF);

[0168] 2) Age ≥18 years;

[0169] 3) Recurrent or metastatic breast cancer confirmed by histology and / or cytology;

[0170] 4) The latest tumor tissue sample was confirmed to be HER2-positive (IHC3+, or IHC2+ and ISH-positive) by central laboratory testing;

[0171] 5) No previous systemic chemotherapy and / or HER2-targeted therapy for recurrent or metastatic breast cancer (subjects who have received one endocrine therapy regimen are allowed to be enrolled); subjects whose disease relapses more than 12 months after the completion of (neo)adjuvant chemotherapy or HER2-targeted therapy may be considered for enrollment;

[0172] 6) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;

[0173] 7) There is at least one measurable or evaluable lesion (RECIST 1.1);

[0174] 8) Have adequate organ and bone marrow function (no blood transfusion or use of hematopoietic stimulating factor drugs within 14 days before the test);

[0175] a) Neutrophil count ≥ 1.5 × 10 9 / L;

[0176] b) Platelet count ≥100×10 9 / L;

[0177] c) Hemoglobin ≥90 g / L;

[0178] d) Liver function: total bilirubin (TBIL) ≤ 1.0 × upper limit of reference value (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for subjects with liver metastasis);

[0179] e) Renal function: creatinine clearance ≥30 mL / min (calculated using the Cockcroft-Gault formula);

[0180] f) Coagulation function: International normalized ratio (INR) ≤ 1.5, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for subjects receiving anticoagulant therapy, the investigator determines that both INR and APTT are within the safe and effective therapeutic range);

[0181] g) left ventricular ejection fraction (LVEF) > 50%;

[0182] 9) Expected survival time ≥ 3 months;

[0183] 10) Female subjects of childbearing age must undergo a blood pregnancy test within 7 days before randomization, with a negative result, and agree to use a reliable and effective method of contraception during the study treatment and within 3 months (docetaxel injection and docetaxel injection (albumin-bound)) or within 7 months (trastuzumab, pertuzumab and KN026) after the last study treatment (whichever is the longest period). Male subjects whose partners are women of childbearing age must agree to use a reliable and effective method of contraception during the study treatment and within 3 months (docetaxel injection and docetaxel injection (albumin-bound)) or within 7 months (trastuzumab, pertuzumab and KN026) after the last study treatment (whichever is the longest period).

[0184] Exclusion criteria

[0185] Subjects who meet any of the following criteria will not be allowed to enter this study:

[0186] 1) Patients with contraindications to trastuzumab, pertuzumab, and docetaxel, or who are deemed unsuitable for KN026 or docetaxel for injection (albumin-bound) by the investigator;

[0187] 2) ALT and / or AST>1.5×ULN and alkaline phosphatase (ALP)>2.5×ULN;

[0188] 3) Subjects with grade 3 or higher peripheral neuropathy at the time of randomization;

[0189] 4) The toxicity of previous anti-tumor treatment has not recovered to Common Terminology Criteria for Adverse Events (CTCAE 5.0) ≤ Grade 1 (excluding toxicities such as alopecia, peripheral neuropathy, and simple laboratory tests that the investigator judges to pose no safety risk, which must be alleviated to ≤ Grade 2);

[0190] 5) Patients whose LVEF has dropped to <50% during previous anti-HER2 drug treatment, or who have developed symptomatic congestive heart failure (CHF), or have experienced toxicity leading to permanent discontinuation of treatment;

[0191] 6) Patients with known allergies and / or contraindications to glucocorticoids (including but not limited to active peptic ulcer, severe hypertension, severe hypokalemia, glaucoma, etc.);

[0192] 7) Patients who have received anthracycline therapy in the past and have reached the following cumulative doses: doxorubicin or liposomal doxorubicin > 360 mg / m 2 Epirubicin >720 mg / m 2 Mitoxantrone >120 mg / m 2 Other anthracyclines > equivalent to 360 mg / m 2 If more than one anthracycline is used, the cumulative dose should not exceed the equivalent of 360 mg / m 2 of doxorubicin;

[0193] 8) Use of strong CYP3A4 inhibitors within 14 days before randomization;

[0194] 9) Contraindications or history of hypersensitivity to any of the study drug ingredients or any known excipients;

[0195] 10) Untreated or unstable brain metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; subjects who have received local brain treatment and have stable symptoms, imaging examinations show stability for at least 4 weeks before randomization, no evidence of brain edema, and do not require glucocorticoid treatment may be considered for inclusion;

[0196] 11) Active malignant tumors within 3 years before randomization, excluding breast cancer studied in this trial and any locally curable tumors that have received radical treatment (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ, early thyroid cancer, etc.);

[0197] 12) With uncontrolled or serious cardiovascular and cerebrovascular diseases, including but not limited to:

[0198] a) New York Heart Association (NYHA) class II or higher congestive heart failure, unstable angina, myocardial infarction, or arrhythmia causing hemodynamic instability within 6 months before randomization;

[0199] b) Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, and unspecified cardiomyopathy);

[0200] c) History of clinically significant QT interval prolongation, or QTcF (calculated using the Fridericia formula) > 450ms during the screening period;

[0201] d) Arterial / venous thrombotic events occurred within 6 months before randomization, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;

[0202] e) uncontrolled hypertension (systolic blood pressure > 160 mmHg and / or diastolic blood pressure > 100 mmHg);

[0203] 13) Severe chronic or active infection (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral treatment within 14 days before randomization;

[0204] 14) Active hepatitis B (HBsAg positive and HBV-DNA ≥ 2×10 3 IU / mL) or hepatitis C (positive hepatitis C antibody and HCV-RNA quantitative test result > lower limit of detection range); Note: For the case where the lower limit of detection range is < HBV DNA < 2×10 3 Hepatitis B virus carriers with a HBV infection rate of ≥10 IU / mL and who are willing to take entecavir or other antiviral treatments based on clinical judgment during the study period may be considered for inclusion;

[0205] 15) Those with a known history of human immunodeficiency virus (HIV) infection;

[0206] 16) Participating in other clinical studies (excluding non-interventional clinical studies or those in the follow-up period of interventional studies) or the time from the end of the previous clinical study (last medication) to the end of randomization is less than 4 weeks;

[0207] 17) Received anti-tumor treatments such as radiotherapy, targeted therapy, immunotherapy, and other clinical research drugs within 28 days before randomization, or used traditional Chinese medicine with anti-tumor indications within 14 days;

[0208] 18. Within 7 days before randomization, there is uncontrollable serous effusion (such as pleural effusion, peritoneal effusion, pericardial effusion, etc.) that requires frequent drainage or medical intervention, or additional intervention is required within 2 weeks after the intervention (excluding exfoliative cytology testing of exudate);

[0209] 19) Underwent major organ surgery (excluding puncture biopsy) within 28 days before randomization;

[0210] 20) Pregnant or breastfeeding women;

[0211] 21) There are other circumstances that may interfere with the subject's participation in the research procedures or are inconsistent with the subject's maximum benefit from participating in the research or affect the research results: such as a history of mental illness, drug abuse or substance abuse, any other clinically significant disease or condition, etc.

[0212] 1.3 Evaluation Metrics

[0213] 1.3.1 Efficacy evaluation

[0214] Radiographic efficacy was evaluated using RECIST 1.1. Efficacy evaluation indicators included:

[0215] ORR: the proportion of subjects with CR and PR among all subjects (assessed by BIRC and investigators);

[0216] (PR: Compared with the baseline sum of target lesion diameters, the sum of target lesion diameters decreased by ≥30%, and non-target lesions did not progress and no new lesions occurred.

[0217] CR: refers to the disappearance of all non-lymph node target lesions and non-target lesions, and no new lesions appear.

[0218] Safety assessments were performed regularly throughout the study, including physical examination, vital signs, weight, 12-lead electrocardiogram, echocardiogram, and laboratory tests. The severity of adverse events was recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE 5.0).

[0219] 2. Research Results

[0220] (1) The results of the efficacy evaluation are as follows:

[0221] As of February 2024, a total of 267 subjects were enrolled, of which 170 had post-baseline efficacy evaluations, including 85 cases in the experimental group and 85 cases in the control group (trastuzumab + pertuzumab + docetaxel). Among the 85 cases in the experimental group, 67 cases had PR, and the ORR was 78.8%. Among the 85 cases in the control group, 56 cases had PR, and the ORR was 65.9%. The PR and ORR values ​​of the experimental group were significantly higher than those of the control group, indicating that the interim ORR data of the experimental group of this application achieved a better anti-tumor efficacy trend than that of the control group.

[0222] (2) The safety assessment results are as follows:

[0223] So far, no new adverse reaction signals have been found in the trial group of this application.

[0224] The combination of anti-HER2 antibody (KN026) and docetaxel albumin for the treatment of HER2-positive recurrent metastatic breast cancer has better anti-tumor efficacy than the existing standard treatment regimen, with good overall safety and more convenient administration. It can provide such patients with a first-line treatment option with better efficacy, good safety and more convenient treatment.

Claims

1. Use of an anti-HER2 antibody and a second therapeutic agent in the preparation of a medicament for treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

2. Use of an anti-HER2 antibody in the preparation of a medicament for enhancing the efficacy of a second therapeutic agent in treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

3. A method for treating cancer using an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

4. A pharmaceutical composition or a kit or a medicine box for treating cancer, comprising an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

5. The use, method, pharmaceutical composition, kit or drug box according to any one of claims 1 to 4, wherein the anti-HER2 antibody is an anti-HER2 bispecific antibody; preferably, the anti-HER2 antibody is a bispecific antibody targeting different epitopes of human HER2 protein; more preferably, the different epitopes of HER2 protein are domain II and domain IV thereof.

6. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 5, wherein the anti-HER2 antibody comprises two common light chains with identical sequences; preferably, the common light chain comprises CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2 and CDR-L3 as shown in SEQ ID NO: 3; more preferably, the common light chain comprises a light chain variable region as shown in SEQ ID NO: 4; further preferably, the common light chain comprises an amino acid sequence as shown in SEQ ID NO:

5.

7. The use, method, pharmaceutical composition, kit or drug box according to any one of claims 1 to 6, wherein the anti-HER2 antibody comprises two heavy chains with different sequences; preferably, the heavy chain comprises heavy chain I targeting HER2 protein domain II, and / or heavy chain II targeting HER2 protein domain IV.

8. The use, method, pharmaceutical composition, kit or drug kit according to claim 7, wherein the heavy chain I comprises CDR-H1-1 as shown in SEQ ID NO: 6, CDR-H1-2 as shown in SEQ ID NO: 7 and CDR-H1-3 as shown in SEQ ID NO: 8; preferably, the heavy chain I comprises the heavy chain I variable region as shown in SEQ ID NO: 9; more preferably, the heavy chain I comprises the amino acid sequence as shown in SEQ ID NO: 10 or SEQ ID NO: 16; and / or, The heavy chain II comprises CDR-H2-1 as shown in SEQ ID NO: 11, CDR-H2-2 as shown in SEQ ID NO: 12 and CDR-H2-3 as shown in SEQ ID NO: 13; preferably, the heavy chain II comprises The heavy chain II variable region is as shown in SEQ ID NO:14; more preferably, the heavy chain II comprises the amino acid sequence as shown in SEQ ID NO:15 or SEQ ID NO:

17.

9. The use, method, pharmaceutical composition, kit or medicine box according to any one of claims 1 to 8, wherein the docetaxel albumin composition comprises docetaxel and acid-denatured albumin; preferably, the docetaxel is selected from anhydrous docetaxel; more preferably, the weight ratio of the docetaxel to the albumin is 1:(4.0-6.0).

10. The use, method, pharmaceutical composition, kit or drug box according to claim 9, wherein the acid-denatured albumin is obtained by denaturing human serum albumin by adding acid to an appropriate pH value; preferably, the acid is cysteine ​​hydrochloride; preferably, the pH value is about 4.

1.

11. The use, method, pharmaceutical composition, kit or drug box according to any one of claims 1 to 10, wherein the docetaxel albumin composition further comprises an osmotic pressure regulator, sodium octanoate; preferably, the osmotic pressure regulator is sodium chloride; more preferably, the weight ratio of the sodium chloride to the docetaxel is about 2.25:1; preferably, the sodium octanoate content is less than 0.16 mmol / g protein; more preferably, the sodium octanoate content is less than 0.08 mmol / g protein.

12. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 11, wherein the cancer includes but is not limited to a hematological tumor or a solid tumor.

13. The use, method, pharmaceutical composition or kit or medicine box of claim 12, wherein the blood tumor is a lymphoma or leukemia, including but not limited to myeloma, B-cell lymphoma, mantle cell lymphoma, non-Hodgkin's B-cell lymphoma, non-Hodgkin's T-cell lymphoma, cutaneous lymphoma, anaplastic large cell lymphoma, multiple myeloma, indolent non-Hodgkin's lymphoma, plasmacytoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma; the solid tumor includes but is not limited to bladder cancer, brain cancer, breast cancer, cervical cancer, chest tumor, endometrial cancer, esophageal squamous cell carcinoma, gastric cancer, head tumor, pancreatic cancer, bile duct cancer, colorectal cancer, eye cancer, head and neck squamous cell carcinoma, urothelial carcinoma, kidney cancer, liver cancer, lymph node cancer, lung cancer, oral cancer, neck tumor, ovarian cancer, prostate cancer, testicular cancer, laryngeal cancer and uterine cancer, melanoma, skin cancer, salivary gland cancer, soft tissue sarcoma and osteosarcoma.

14. The use, method, pharmaceutical composition, kit or drug box according to claim 12, wherein the solid tumor is breast cancer; preferably, the breast cancer is HER2-positive breast cancer; more preferably, the breast cancer is HER2-positive recurrent and / or metastatic breast cancer.

15. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 14, wherein the anti-HER2 antibody and the second therapeutic agent are contained in the same preparation unit, or are respectively contained in separate preparation units.

16. The use, method, pharmaceutical composition, kit or medicine box according to any one of claims 1 to 15, wherein the docetaxel albumin composition is formulated into a preparation, and each preparation unit contains 50-100 mg of docetaxel (calculated as anhydrous docetaxel), preferably 70-90 mg, and more preferably about 80 mg; and / or, the anti-HER2 antibody is formulated into a preparation, and the content of the anti-HER2 antibody or a pharmaceutically acceptable form thereof (calculated as anhydrous anti-HER2 antibody) in each preparation unit is in the range of about 0.01 mg to about 400 mg, preferably 300-400 mg, more preferably about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg.

17. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 16, wherein the docetaxel albumin composition is administered at a dose of 60-125 mg / m 2 , preferably 60-100 mg / m 2 , more preferably about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 ; and / or, the anti-HER2 antibody is administered at a dose of: 0.01 mg / kg-100 mg / kg, preferably 20-40 mg / kg, 20 mg / kg-30 mg / kg, 25 mg / kg-35 mg / kg, more preferably about 30 mg / kg.

Citation Information

Patent Citations

  • Bispecific antibody or antibody mixture with common light chains

    WO2016110267A1

  • Stable docetaxel albumin nanoparticle composition

    WO2022184164A1

  • Bispecific antibody or antibody mixture having common light chain

    CN105820251A

  • Solid composition containing docetaxel and human serum albumin and preparation method and application thereof

    CN112807299A

  • Stable docetaxel albumin nanoparticle composition

    CN115025053A